Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Chemotherapy +/- AI in Advanced Breast Cancer
NCT00687648Phase 2Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- May 2008
- Primary completion
- Apr 2010
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anastrozole, letrozole and exemestane in breast cancer (2 arms), sponsored by National Cancer Centre Singapore. Primary endpoint: Clinical Benefit Response Rate at 24 weeks. Status: unknown.
02
Drugs
anastrozoleletrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00687648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687648.